BlogHeader.png

Alcami Presenting at the 2017 Laboratory Design Conference

Alcami presented at the 2017 Laboratory Design Conference, held April 24-26, 2017 in Raleigh, North Carolina. 

The presentation discussed renovating Alcami's laboratory space in its Wilmington, NC headquarters, and focused on these three perspectives: Lab Planning, Engineering and Owner Requirements. The team provided strategies for how to renovate an existing facility and maintain existing operations throughout the construction period.

Topics: Events

Alcami Attending AAPS National Biotechnology Conference 2017

                         
Alcami will be exhibiting and presenting at the AAPS National Biotechnology Conference 
May 1-3, 2017 in San Diego, CA.

Visit Alcami at booth #415 to speak with our technical experts, meet with our sales team, and learn more about us.

Donald F. DeCou, Ph.D., Principal Scientist- Biotechnology will be presenting at the Learning Lounge on May 2, 2017 from 2:30pm – 2:50pm in the Pacific Ballroom at the San Diego Marriott Marquis. The talk, Extractables and Leachables: Testing in Biologics and Medical Devices, will provide a brief overview of regulatory requirements with extractable and leachables testing in biologics and medical devices, as well as a comprehensive discussion on examples and case studies.

Topics: Events

Bringing the Light to Photostability in Three Parts - Part 2

Part 2: Forced Degradation Studies to Support Photostability  

In Part One of this photostability blog series, a high level review on the background of photostability was presented.  In this second part, work leading up to the execution of a photostability study on Active Pharmaceutical Ingredient (API) and pharmaceutical products will be discussed. 

Prior to execution of a photostability study, the analytical test procedures (TP) must demonstrate the ability to detect degradants caused by photolysis (photodegradation).  Not all compounds are susceptible to photolysis; a molecule must absorb the UV or visible light energy to be susceptible to this phenomenon.  For example, if the absorption spectrum of a molecule has a maximum of ~254 nm and with minimal or no absorption above 300 nm, this molecule would not be susceptible to photodegradation during an ICH photostability study as the lowest wavelength of exposure is ~320 nm. 

Topics: Thought Leadership

Alcami Announces Extended Workbench Offering for Analytical Services

Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, announces an extended, comprehensive service program that allows clients the flexibility, freedom and consistent control of outsourced laboratory needs. Our Extended Workbench is a Full-Time Equivalent (FTE) program tailored to  a client’s needs. The Extended Workbench program is effective across any pharmaceutical arena with its capacity that can vary greatly in size, management and scope.

Topics: Company News

Editorial: Formulation Development & Manufacturing — CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs

Alcami recently contributed to a special feature in Drug Development and Delivery magazine titled "Formulation Development & Manufacturing — CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs." The article includes Alcami, along with other CDMOs highlighting their capabilities in the areas of speed, quality, technology, and handling of complex APIs.

Topics: Thought Leadership

Alcami Exhibiting and Presenting at CPhI Japan April 19 - 21, 2017

Alcami will be exhibiting at CPhI Japan, to be held on April 19 - 21 in Tokyo. Visit us at stand T10, located in East Hall 2 of the Tokyo Big Sight Exhibition Centre! 

Topics: Events

Bringing the Light to Photostability in Three Parts

Part 1: Basic Requirements – Setting the Stage

ICH Guidance Q1B was published in 1996 describing a harmonized approach to photostability studies.  Although it has been 20+ years since its publishing, questions still arise on how to execute a photostability study and how to interpret the results.  In this blog series, I will address common questions and detail how a photostability study is executed.  At Alcami, photostability is conducted at three laboratory sites: Wilmington, NC; Edison, NJ; and St. Louis, MO.

A photostability study is performed using either a full spectrum light source that produces a spectrum similar to D65/ID65 emission standard, or two separate light sources: one for near UV radiation with a spectral distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm and 370 nm, and a second light source that is a cool white fluorescent lamp designed to produce an output similar to that specified in ISO 10977.  Regardless of which approach is taken, the objective is to expose samples to an integrated amount of NLT 200 Watt·hrs/m2 of near-ultraviolet energy and NLT 1.2 million lux·hours of visible light. 

Topics: Thought Leadership

Elemental Impurities – Highlights of the Coming Regulation

Replacement of the wet chemistry “heavy metals” limit tests with more modern analytical methodology and conformance to new and specific limits for individual elements was a dramatic, although anticipated, change in the regulation.

The ICH recognized that prior to the Q3D Guidance, regulation of elemental impurities fell under Guideline Q3A for inorganic impurities. Existing pharmacopoeial procedures included the Heavy Metals test, Residue on Ignition/Sulfated Ash test and other wet chemistry tests. The problem with these procedures was that they were non-specific and were never intended to detect the low-level residual metal catalysts and reagents used in some modern synthetic processes. In addition, the acceptance criteria were based upon historical precedent and, although risk factors for metal contamination had changed significantly throughout the 20th century, the existing limits had not changed accordingly and had little toxological basis.

Topics: Regulatory Compliance

ON-DEMAND WEBINAR: Elemental Impurities - Everything You Need to Know

The introduction of new guidelines relating to elemental impurities in pharmaceuticals from the International Conference on Harmonization (ICH), U.S. Food and Drug Administration (FDA) and United States Pharmacopeia (USP) has created new and complex challenges for the pharmaceutical industry. These challenges include replacing the wet chemistry “heavy metals” limit test with new analytical technology, specifically, inductively coupled plasma (ICP) –based technologies and mandated conformance to new and specific limits for individual elements.  From a compliance perspective, the new guidance for elemental impurities (USP<232>and ICH Q3D) only applies to the drug product and the materials/processes involved.

Are you ready for this regulatory change?

Topics: Webinars

ENCORE WEBINAR: Critical Drug Substance Considerations for Formulation Success in Drug Product Development

Join Alcami for a webinar on Thursday, April 6, discussing critical drug substance considerations for formulation success in drug product development.

Understanding the solid state properties of a drug candidate molecule is of critical importance for successful dosage form development. It takes close collaboration and communication between solid state characterization scientists, synthetic process chemists, analysts and engineers, and formulation development personnel to reduce risk, both in time and cost.

Alcami’s ProForm Select™ is a unique offering designed to provide pharma and biotech companies a control strategy that is integrated and end-to-end, reducing process instability which can delay clinical milestones or commercial supply. From development to clinical and commercial, this service offers the unique integration of API process chemistry and Drug Product formulation development in parallel, driving right-first-time results.

This webinar will present the ProForm Select™ offering, featuring solutions to your biggest development challenges:

  • Selection, optimization of API process, drug product formulation, and control of end-to-end manufacturing process
  • Integrated and simplified supply chain for development and manufacturing
  • Reduced timelines and cost through parallel development and cyclical process feedback
Topics: Webinars